关键词: Alveolar soft part sarcoma Computer tomography Metastatic disease Soft tissue sarcoma

Mesh : Adult Antineoplastic Agents / therapeutic use Crizotinib / therapeutic use Female Humans Lung Neoplasms / diagnostic imaging drug therapy secondary Male Sarcoma, Alveolar Soft Part / diagnostic imaging drug therapy pathology Soft Tissue Neoplasms / diagnostic imaging drug therapy pathology Tomography, X-Ray Computed / methods standards

来  源:   DOI:10.1186/s40644-020-00352-9   PDF(Sci-hub)   PDF(Pubmed)

Abstract:
BACKGROUND: Alveolar Soft Part Sarcoma (ASPS) is a rare, slow-growing, but highly vascular soft tissue sarcoma, characterised by a high rate of metastases at presentation. Although imaging features of the primary are well described, less detail is available on the imaging pattern of metastatic ASPS. The EORTC 90101 (CREATE) study assessed the efficacy of Crizotinib in patients with metastatic ASPS and presents a unique opportunity to describe the imaging phenotype of primary and metastatic ASPS, based on prospectively collected imaging.
METHODS: A retrospective review of the staging CT scans of 32 patients with ASPS from the CREATE study was undertaken and the imaging features of primary and metastatic disease were assessed.
RESULTS: Imaging of the primary tumour was available in 7/32 cases (28%). All primary tumours demonstrated marked vascularity with prominent feeding vessels (7/7, 100%). The most frequent sites of metastases included lung (30/32, 94%), nodal (7/32, 22%), bone (5/32, 16%) and muscle/subcutaneous (5/32, 16%). Features of hypervascularity were identified at all sites, more appreciable in the lungs, with feeding vessels frequently demonstrated in pulmonary metastases (21/32, 66%).
CONCLUSIONS: Analysis of imaging from the CREATE cohort of patients with metastatic ASPS demonstrates that metastases from ASPS are predominantly hypervascular and demonstrate feeding vessels comparable to primary ASPS, suggesting potential sensitivity of this rare sarcoma for antivascular/antiangiogenic treatment approaches.
摘要:
暂无翻译
公众号